ArticleAmerican journal of translational research2021
CCR10/CCL27 crosstalk regulates cell metastasis via PI3K-Akt signaling axis in non-small-cell lung cancer.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 9 citations in OpenAlex.
- Inflammatory Mediators of Alzheimer's Disease Characterized in a Mouse Model (APP/PS1).NeuroSci · 2026Article
- Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.Biomarker research · 2025Review
- The Use of Biologics for Targeting GPCRs in Metastatic Cancers.Biotech (Basel (Switzerland)) · 2025Review
- CCR10: a comprehensive review of its function, phylogeny, role in immune cell trafficking and disease pathogenesis.Frontiers in immunology · 2025Review
- The pivotal role of cytokines in liver disease pathogenesis and therapeutic potential.Frontiers in immunology · 2025Review
- A causal association between chemokines and the risk of lung cancer: a univariate and multivariate mendelian randomization study.Journal of cardiothoracic surgery · 2024Article
- Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study.BMC cancer · 2024Article
- Inhibition of cc chemokine receptor 10 ameliorates osteoarthritis via inhibition of the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin pathway.Journal of orthopaedic surgery and research · 2024Article
- The CCL27-CCR10 axis contributes to promoting proliferation, migration, and invasion of lung squamous cell carcinoma.Histology and histopathology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous research has shown that CCR10 acts as a vital oncogene in the progression of multiple malignancies. However, its effect on the treatment of non-small-cell lung cancer (NSCLC) has not been investigated. Current research examined the effect of CCR10 on the cellular survival and migration of NSCLC, and the modulation of cell death and found that the expression levels of CCR10 and CCL27 (ligand) were highly upregulated in human NSCLC tissue and cell lines, A549 and H157, compared with adjacent normal lung specimens. MTT and colony formation assays revealed that the blockage of CCR10 inhibited the multiplication and survival of A549 and H157 cells. Further study showed that metastasis-relevant VEGF-C/D, MMP-2/9, TIMP-1/2 were also regulated via CCR10 activation. Notably, increased NF-κB levels were detected in cells with activated CCR10, whereas the levels of NF-κB decreased in cells with blocked CCR10. Finally, the recovery of NF-κB expression counteracted the suppressive influence of CCR10 blockage on NSCLC cell survival, migration, and invasion. These results improved our knowledge understanding the molecular mechanisms of CCR10-CCL27 in progression of NSCLC.
Indexed as
Identifiers
34956534PMC8661166W4206878177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.